Silver and titanium dioxide nanoparticles bullets against multi-drug-resistant gram-negative urine-bacteria beside their antineoplastic activity to HepG2 cell line

Background: Multidrug-resistant (MDR) bacteria are a fundamental risk and cause of fatal chronic infections. Objectives: Evaluate Silver and Titanium NPs antibacterial activity in addition to their anticancer potential against HepG2 cell line. Materials and methods: The nanoparticles were characterized after their synthesis by investigating their optical, morphological structure, and colloidal properties using UV-Vis absorption spectral analysis, transmission electron microscopy (TEM), X-ray diffraction analysis (XRD), and dynamic light scattering (DLS) techniques. Results: The present study characterized twenty-two isolated bacterial species as MDR strains based on their resistance to antibiotic examinations and tested the antibacterial activity of silver (AgNPs) and titanium dioxide (TiO2NPs) nanoparticles against urinary tract bacterial strains. The average particle size of AgNPs and TiO2NPs was 30±5, and 20±5 nm with cubic and anatase crystal structures, respectively. AgNPs showed a minimal inhibition concentration (MIC) within the range of 4 to 8 μg/mL, which is lower than TiO2NPs ranging from 500 to 1000 μg/mL. Also, AgNPs are the most effective antimicrobials, with inhibition zones that are between 31 and 33 mm wide and cover ten different types of Klebsiella pneumonia. On the other hand, TiO2NPs showed remarkable antibacterial efficacy against MDR isolates with inhibition zones of about 31–33 mm. The most extensive MDR bacterial strains were Klebsiella pneumoniaA031 [OP811040] and Klebsiella pneumoniaA065 [OP811041]. TiO2NPs had less toxicity on the same types of HepG-2 cells, than Ag NPs as toxicity appeared at a concentration higher than 125 µg/ml; it was 3.2% at 250 µg/ml, then 28.2% at 500 µg/ml, and finally 90.2% at 1000 µg/ml. Conclusion: our results investigate promising antibacterial and anticancer activity of two prepared Ag and TiO2NPs particularly against Klebsiella pneumonia and HepG2 cell line.